The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors

Carolyn Katovich Hurley,1 Ann Woolfrey,2 Tao Wang,3 Michael Haagenson,4 John Umejeigo,4 Mahmoud Aljurf,6 Medhat Askar,6 Minoo Battiwalla,7 Jason Dehn,6 John Horan,8 Machtedl Oudshoorn,10 Joseph Pidala,11 Wael Saber,12 Victoria Turner,13 Stephanie J. Lee,2 and Stephen R. Spellman4

1Georgetown University, Washington, DC; 2Fred Hutchinson Cancer Research Center, Seattle, WA; 3Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI; 4Center for International Blood and Marrow Transplant Research, Minneapolis, MN; 5King Faisal Specialist Hospital, Riyadh, Saudi Arabia; 6Cleveland Clinic Lerner College of Medicine, Cleveland, OH; 7Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD; 8National Marrow Donor Program, Minneapolis, MN; 9Emory University, Atlanta, GA; 10Europdonor Foundation and the Leiden University Medical Center, Leiden, The Netherlands; 11H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; 12Medical College of Wisconsin, Milwaukee, WI; and 13St. Jude Children’s Research Hospital, Memphis, TN

Key Points

- Unidirectional graft-versus-host vector 7/8 HLA mismatches have the same level of risk as bidirectional 7/8 mismatches.
- For HLA homozygous recipients, a mismatch at the homozygous locus is preferred over a mismatch at the heterozygous loci.

The impact of HLA homozygosity at mismatched (MM) loci on the outcome of 2687 myeloablative unrelated donor hematopoietic cell transplantations performed for malignant disease was evaluated among 4 groups: 7/8 bidirectional MM transplants (donor and recipient heterozygous MM, n = 1393), 7/8 host-versus-graft (HVG) vector MM (recipient homozygous, n = 112), 7/8 graft-versus-host (GVH) vector MM (donor homozygous, n = 119), and 8/8 matches (n = 1063). Multivariate analyses found 7/8 GVH (P = .001) and bidirectional MM groups (P < .0001) had significantly worse transplant-related mortality and overall and disease-free survival than the 8/8 match group, a difference not observed with the 7/8 HVG MM group (P > .01). The 3 7/8 groups differed only for grades III-IV acute GVH disease (GVHD), where HVG MM had less GVHD than the 7/8 bidirectional MM (hazard ratio [HR] 0.52, P = .0016) and GVH MM (HR 0.43, P = .0009) groups but not the 8/8 group (HR 0.83, P = .39). There were no differences between the 7/8 groups for relapse, chronic GVH, neutrophil engraftment, or graft failure. GVH MM have the same risk as 7/8 bidirectional MM. 7/8 HVG MM confer a reduced risk of acute GVHD without an increased risk of disease relapse or graft failure compared with a 7/8 bidirectional MM. (Blood. 2013;121(23):4800-4806)

Introduction

Recipients of hematopoietic stem cell transplantations are matched with their unrelated adult volunteer donors for HLA-A, HLA-B, HLA-C, and HLA-DRB1 high-resolution types (ie, 8/8 match) to optimize overall survival.1,2 Each allelic mismatch reduces overall survival at 1 year by 9% to 10% (8/8 52%, 7/8 43%, 6/8 33%).3 For those patients without 8/8 matched donors, there is no consensus as to how homozygosity at an HLA locus should be handled in determining the degree of mismatch between a patient and a potential donor. Unidirectional mismatches may affect the rates of graft failure for a homozygous recipient receiving a graft from a heterozygous donor (ie, mismatch in the host-versus-graft [HVG] vector; R: A*02:01,*02:01 and D: A*02:01, *11:01) or graft-versus-host (GVH) disease for a homozygous donor (ie, mismatch in the GVH vector) (Table 1). If both donor and recipient are homozygous and mismatched (eg, A*02:01, *02:01 vs A*11:01, *11:01), the bidirectional mismatch may affect both outcomes.

A study by the Seattle Transplant Group4 suggested that the risk of graft failure was increased if the recipient of a bone marrow graft was HLA homozygous at the mismatched class I locus (ie, in the HVG vector). Of the 471 donor-recipient pairs studied, primary graft failure was observed in 26 patients and secondary failure in 2. Of the 7 recipients homozygous at the mismatched class I locus, 5 exhibited graft failure, compared with 7 of the 98 heterozygous recipients (P value <.001). An increased percentage of homozygous recipients with multiple class I mismatches also showed more frequent graft failure compared with heterozygous recipients with multiple mismatches. Based on these data, the investigators suggested that mismatches at the recipient’s homozygous loci should be avoided.

This study reevaluated the outcome for unidirectional mismatches in recipients receiving either bone marrow or growth factor stimulated peripheral blood grafts for malignant diseases. The hypothesis tested was that unidirectional mismatches will have outcomes
indistinguishable from 7/8 bidirectional mismatched transplantations. Comparisons in outcomes were also made to 8/8 matched transplantations.

### Methods

#### Study population

The study included patients reported to the National Marrow Donor Program (NMDP) who received a transplant from an unrelated donor between 1988 and 2009. The study population consisted of recipients receiving their first marrow or peripheral blood stem cell unrelated donor transplantation for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), or myelodysplastic syndrome (MDS). Early-stage disease was defined as AML or ALL in first complete remission, CML in first chronic phase, and MDS subtype refractory anemia. Intermediate-stage disease was defined as AML or ALL in second or subsequent complete remission and CML in accelerated phase or second chronic phase. Advanced-phase disease was defined as AML in first or higher relapse or primary induction failure, CML in blast phase, and MDS subtypes refractory anemia with excess blasts or in transformation.

All surviving recipients included in this analysis were retrospectively contacted and provided informed consent for participation in the NMDP research program, in accordance with the Declaration of Helsinki. Research was approved and conducted under the supervision of the NMDP Institutional Review Board. A modeling process was used, as previously described in Lee et al. and Farag et al., to adjust for any bias introduced by the exclusion of nonconsenting survivors.

All HLA-typing was verified using DNA-based methods at high resolution, as previously described in Spellman et al. Cases were divided into 4 histocompatibility groups based on high-resolution typing at HLA-A, HLA-B, HLA-C, and HLA-DRB1 loci (Table 2). The comparison groups included (1) both donor and recipient with a single high-resolution mismatch (ie, mismatches altering the polypeptide sequence of the HLA antigen recognition site, including both allele and antigen mismatches) and both heterozygous at the mismatched (MM) locus (eg, A*02:01, A*03:01 vs A*02:01, A*03:01) (7/8 bidirectional MM); (2) the recipient homozygous for the mismatched locus (unidirectional 7/8 HVG), (3) the donor homozygous for the mismatched locus (7/8 GVH), and (4) 8/8 high resolution HLA-A, HLA-B, HLA-C, HLA-DRB1 matched transplants exhibiting homozygosity at 1 or more loci (8/8) (Table 1). This restriction was imposed for the 8/8 group to increase the comparability with the 7/8 groups of interest. A univariate analysis comparing outcomes between the 8/8 comparison group (n = 1063) and 8/8 matches where donor and recipient were heterozygous at the matched loci (n = 3619) noted no significant differences in overall survival, transplant-related mortality (TRM), disease-free survival, neutrophil engraftment, secondary graft failure, or acute and chronic GVHD disease (GVHD). Significant differences were noted in the probability of relapse at 3 years (P = .003) and 5 years (P = .006), where 8/8 heterozygotes had a slightly greater likelihood of relapse (30% [95% confidence interval (CI) 29-32] for 8/8 heterozygotes vs 26% [95% CI 23-28] for 8/8 with 1 or more homozygous loci at 3 years. Unfortunately, the evaluation of bidirectional mismatches in homozygous recipients and donors could not be evaluated due to the low number of cases (3 total).

The study evaluated the associations between histocompatibility groups and outcomes with overall survival and disease-free survival as primary end points, and acute GVHD, chronic GVHD, TRM, relapse, neutrophil engraftment, and graft failure as secondary end points. Overall survival considered death from any cause as the event, and surviving patients were censored at the date of last contact. Disease-free survival was defined as relapse or death from any cause, with patients who were alive and in complete remission censored at the time of last follow-up. The incidences of grades II-IV or III-IV acute GVHD were determined during the first 100 days after transplant and defined according to the Glucksberg scale. Chronic GVHD included limited and extensive conditions and was defined according to the Seattle criteria. TRM was defined as death during a continuous, complete remission. Relapse was defined as leukemia relapse or MDS recurrence. Neutrophil engraftment was defined as achieving an absolute neutrophil count greater than 500 cells per milliliter or loss of donor chimerism. Patients receiving second transplants for reasons other than relapse were also considered to have graft failure. Only those cases of graft failure that occurred within a year of the first transplant were included in the graft failure analysis. Events were summarized by the cumulative incidence estimate, with death as the competing risk.

### Statistical methods

To compare pretransplant characteristics for discrete factors, the number of cases and their respective percentages were calculated and χ² tests were performed to compare the 4 histocompatibility groups. For continuous factors, the medians and ranges were calculated and the Kruskal-Wallis test was used to analyze differences between the groups. Probabilities of disease-free survival were calculated using the Kaplan-Meier estimator. Estimated cumulative incidence was used to describe the probabilities for events with competing risks. These included engraftment, GVHD, relapse, and TRM. Comparisons of survival curves were done with the log-rank test.

Multivariate analyses were performed using the Cox proportional hazards model to compare the histocompatibility groups. Models were fit to determine which risk factors were related to a given outcome. All variables were tested for confirmation of the proportional hazards assumption. Factors violating the proportional hazards assumption were adjusted through stratification. A stepwise model building procedure was used to select risk factors for each outcome with a threshold of P < .05 for entering into the models. Due to multiple comparisons, P < .01 was used to determine statistical significance for the main effect. All analyses were performed using SAS version 9.2 (SAS Institute, Inc.).

---

**Table 1. Examples of HLA histocompatibility groups in study**

<table>
<thead>
<tr>
<th>Donor (graft)*</th>
<th>Recipient (host)*</th>
<th>Match category† (A, B, C, DRB1)</th>
<th>Vector of mismatch</th>
<th>Guideline for 7/8 matching</th>
</tr>
</thead>
<tbody>
<tr>
<td>A<em>02:01, A</em>02:01</td>
<td>A<em>02:01, A</em>02:01</td>
<td>8/8 match</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Homozygous</td>
<td>Homozygous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A<em>02:01, A</em>03:01</td>
<td>A<em>02:01, A</em>02:01</td>
<td>7/8 mismatch</td>
<td>HVG</td>
<td>Less risk of GVHD compared with bidirectional mismatch</td>
</tr>
<tr>
<td>Heterozygous</td>
<td>Homozygous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A<em>02:01, A</em>02:01</td>
<td>A<em>03:01, A</em>02:01</td>
<td>7/8 mismatch</td>
<td>GVH</td>
<td>Same risks as bidirectional mismatch</td>
</tr>
<tr>
<td>Homozygous</td>
<td>Heterozygous</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A<em>01:01, A</em>02:01</td>
<td>A<em>03:01, A</em>02:01</td>
<td>7/8 mismatch</td>
<td>Bidirectional (HVG and GVH)</td>
<td></td>
</tr>
<tr>
<td>Heterozygous</td>
<td>Heterozygous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Examples only; mismatches at all 4 loci, HLA-A, HLA-B, HLA-C, and HLA-DRB1, were included in study. Mismatched alleles are highlighted in bold text.†Match category assumes that alleles at all other loci (B, C, DRB1) are matched in these examples.
Table 2. Characteristics of recipients receiving myeloablative first transplants for AML, ALL, CML, or MDS that are high-resolution typed for HLA-A, HLA-B, HLA-C, and HLA-DRB1 by HLA categories*†

<table>
<thead>
<tr>
<th>Variable</th>
<th>8/8 Matched N (%)</th>
<th>7/8 HVG MM N (%)</th>
<th>7/8 GVH MM N (%)</th>
<th>7/8 Both Directions N (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>1063</td>
<td>112</td>
<td>119</td>
<td>1393</td>
<td>.0001</td>
</tr>
<tr>
<td>Number of centers</td>
<td>124</td>
<td>63</td>
<td>60</td>
<td>147</td>
<td>---------</td>
</tr>
<tr>
<td>Recipient age, median (range), y</td>
<td>38 (1-70)</td>
<td>34 (4-64)</td>
<td>31 (1-65)</td>
<td>33 (1-69)</td>
<td>.0001</td>
</tr>
<tr>
<td>Age at transplant, y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-9</td>
<td>76 (7)</td>
<td>8 (7)</td>
<td>17 (14)</td>
<td>141 (10)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>10-19</td>
<td>105 (10)</td>
<td>18 (16)</td>
<td>16 (13)</td>
<td>199 (14)</td>
<td></td>
</tr>
<tr>
<td>20-29</td>
<td>180 (17)</td>
<td>16 (14)</td>
<td>23 (19)</td>
<td>250 (18)</td>
<td></td>
</tr>
<tr>
<td>30-39</td>
<td>209 (20)</td>
<td>35 (31)</td>
<td>22 (18)</td>
<td>284 (20)</td>
<td></td>
</tr>
<tr>
<td>40-49</td>
<td>272 (26)</td>
<td>19 (17)</td>
<td>21 (18)</td>
<td>317 (23)</td>
<td></td>
</tr>
<tr>
<td>50 and older</td>
<td>221 (21)</td>
<td>16 (14)</td>
<td>20 (17)</td>
<td>202 (15)</td>
<td></td>
</tr>
<tr>
<td>Recipient race</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>955 (90)</td>
<td>90 (80)</td>
<td>106 (89)</td>
<td>1121 (80)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>African American</td>
<td>33 (3)</td>
<td>11 (10)</td>
<td>5 (4)</td>
<td>9 (7)</td>
<td></td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>22 (2)</td>
<td>5 (4)</td>
<td>5 (4)</td>
<td>27 (2)</td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>41 (4)</td>
<td>6 (5)</td>
<td>5 (4)</td>
<td>133 (10)</td>
<td></td>
</tr>
<tr>
<td>Native American</td>
<td>3 (1)</td>
<td>5 (4)</td>
<td>6 (5)</td>
<td>6 (5)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>9 (1)</td>
<td>0</td>
<td>0</td>
<td>14 (1)</td>
<td></td>
</tr>
<tr>
<td>Male sex</td>
<td>609 (57)</td>
<td>61 (54)</td>
<td>58 (49)</td>
<td>771 (55)</td>
<td>.31</td>
</tr>
<tr>
<td>Karnofsky prior to transplant ≥90</td>
<td>717 (73)</td>
<td>74 (66)</td>
<td>74 (66)</td>
<td>934 (71)</td>
<td>.42</td>
</tr>
<tr>
<td>Disease at transplant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>.003</td>
</tr>
<tr>
<td>AML</td>
<td>399 (38)</td>
<td>44 (39)</td>
<td>43 (36)</td>
<td>503 (36)</td>
<td></td>
</tr>
<tr>
<td>ALL</td>
<td>225 (21)</td>
<td>24 (21)</td>
<td>25 (21)</td>
<td>378 (27)</td>
<td></td>
</tr>
<tr>
<td>CML</td>
<td>270 (25)</td>
<td>32 (29)</td>
<td>25 (21)</td>
<td>362 (26)</td>
<td></td>
</tr>
<tr>
<td>MDS</td>
<td>169 (16)</td>
<td>12 (11)</td>
<td>17 (14)</td>
<td>150 (11)</td>
<td></td>
</tr>
<tr>
<td>Disease status at transplant</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>.96</td>
</tr>
<tr>
<td>Early</td>
<td>762 (72)</td>
<td>79 (71)</td>
<td>83 (70)</td>
<td>978 (70)</td>
<td></td>
</tr>
<tr>
<td>Intermediate</td>
<td>57 (5)</td>
<td>8 (7)</td>
<td>7 (6)</td>
<td>86 (6)</td>
<td></td>
</tr>
<tr>
<td>Advanced</td>
<td>244 (23)</td>
<td>25 (22)</td>
<td>29 (24)</td>
<td>329 (24)</td>
<td></td>
</tr>
<tr>
<td>Graft type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>.003</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>648 (61)</td>
<td>76 (66)</td>
<td>84 (71)</td>
<td>942 (68)</td>
<td></td>
</tr>
<tr>
<td>Peripheral blood stem cell</td>
<td>415 (39)</td>
<td>36 (32)</td>
<td>35 (29)</td>
<td>451 (32)</td>
<td></td>
</tr>
<tr>
<td>In vivo T-cell depletion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>.01</td>
</tr>
<tr>
<td>No</td>
<td>850 (80)</td>
<td>75 (67)</td>
<td>92 (77)</td>
<td>1069 (77)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>213 (20)</td>
<td>37 (33)</td>
<td>27 (23)</td>
<td>324 (23)</td>
<td></td>
</tr>
<tr>
<td>GVHD prophylaxis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>.001</td>
</tr>
<tr>
<td>Tacrolimus ± other</td>
<td>558 (52)</td>
<td>54 (48)</td>
<td>51 (43)</td>
<td>624 (45)</td>
<td></td>
</tr>
<tr>
<td>Cyclosporine ± other</td>
<td>505 (48)</td>
<td>58 (52)</td>
<td>68 (57)</td>
<td>769 (55)</td>
<td></td>
</tr>
<tr>
<td>Donor/recipient sex match</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>.004</td>
</tr>
<tr>
<td>Male/male</td>
<td>436 (41)</td>
<td>34 (30)</td>
<td>40 (34)</td>
<td>482 (35)</td>
<td></td>
</tr>
<tr>
<td>Male/female</td>
<td>269 (25)</td>
<td>24 (21)</td>
<td>35 (29)</td>
<td>335 (24)</td>
<td></td>
</tr>
<tr>
<td>Female/male</td>
<td>173 (16)</td>
<td>27 (24)</td>
<td>18 (15)</td>
<td>289 (21)</td>
<td></td>
</tr>
<tr>
<td>Female/female</td>
<td>185 (17)</td>
<td>27 (24)</td>
<td>26 (22)</td>
<td>287 (21)</td>
<td></td>
</tr>
<tr>
<td>Number of patients</td>
<td>1063</td>
<td>112</td>
<td>119</td>
<td>1393</td>
<td></td>
</tr>
<tr>
<td>Donor/recipient CMV match</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>.02</td>
</tr>
<tr>
<td>Negative/negative</td>
<td>354 (33)</td>
<td>38 (34)</td>
<td>42 (35)</td>
<td>426 (31)</td>
<td></td>
</tr>
<tr>
<td>Negative/positive</td>
<td>334 (31)</td>
<td>32 (29)</td>
<td>37 (31)</td>
<td>387 (28)</td>
<td></td>
</tr>
<tr>
<td>Positive/negative</td>
<td>136 (13)</td>
<td>17 (15)</td>
<td>23 (19)</td>
<td>214 (15)</td>
<td></td>
</tr>
<tr>
<td>Positive/positive</td>
<td>190 (18)</td>
<td>21 (19)</td>
<td>15 (13)</td>
<td>319 (23)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>49 (5)</td>
<td>4 (4)</td>
<td>2 (2)</td>
<td>47 (3)</td>
<td></td>
</tr>
<tr>
<td>Interval from diagnosis to transplant</td>
<td>9 (&lt;1-296)</td>
<td>9 (&lt;1-248)</td>
<td>9 (&lt;1-75)</td>
<td>11 (&lt;1-309)</td>
<td>.002</td>
</tr>
<tr>
<td>HLA matching: HLA-A, HLA-B, HLA-C, and HLA-DRB1</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA-DRB1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8/8 matched</td>
<td>1063 (100)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>HLA-A 1 mismatch (MM)</td>
<td>0</td>
<td>34 (30)</td>
<td>47 (39)</td>
<td>420 (30)</td>
<td></td>
</tr>
<tr>
<td>HLA-B 1 MM</td>
<td>0</td>
<td>7 (6)</td>
<td>9 (8)</td>
<td>225 (16)</td>
<td></td>
</tr>
<tr>
<td>HLA-C 1 MM</td>
<td>0</td>
<td>57 (51)</td>
<td>58 (49)</td>
<td>617 (44)</td>
<td></td>
</tr>
<tr>
<td>HLA-DRB1 1 MM</td>
<td>0</td>
<td>14 (13)</td>
<td>5 (4)</td>
<td>131 (9)</td>
<td></td>
</tr>
</tbody>
</table>

*Data has been modeled to adjust for oversampling of deceased patients due to a lack of consent for NMDP cases before 2003.
†Completeness index follows: Percent with 1-year follow-up: overall: 99%; percent with 3-year follow-up: overall: 95%; percent with 5-year follow-up: overall: 89%.
‡One or more locus is homozygous in the 8/8 matched category.
§This figure is the log-rank P value.
Table 2. (continued)

<table>
<thead>
<tr>
<th>Variable</th>
<th>8/8§ Matched N (%)</th>
<th>7/8 HVG MM N (%)</th>
<th>7/8 GVH MM N (%)</th>
<th>7/8 Both Directions N (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Donor age</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donor age, median</td>
<td>34 (18-58)</td>
<td>36 (20-56)</td>
<td>38 (19-57)</td>
<td>36 (19-61)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Donor age, range</td>
<td>18-29</td>
<td>32 (28)</td>
<td>22 (18)</td>
<td>34 (25)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>30-39</td>
<td>418 (39)</td>
<td>37 (33)</td>
<td>49 (41)</td>
<td>520 (37)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>40-49</td>
<td>235 (22)</td>
<td>38 (34)</td>
<td>37 (31)</td>
<td>396 (29)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>50 and older</td>
<td>58 (5)</td>
<td>6 (5)</td>
<td>11 (9)</td>
<td>132 (9)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td><strong>Donor race</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>925 (87)</td>
<td>82 (73)</td>
<td>98 (82)</td>
<td>1063 (76)</td>
<td>.005</td>
</tr>
<tr>
<td>African American</td>
<td>20 (2)</td>
<td>7 (6)</td>
<td>7 (6)</td>
<td>90 (6)</td>
<td>.006</td>
</tr>
<tr>
<td>Asian/Pacific Island</td>
<td>22 (2)</td>
<td>5 (4)</td>
<td>5 (4)</td>
<td>32 (2)</td>
<td>.013</td>
</tr>
<tr>
<td>Hispanic</td>
<td>39 (4)</td>
<td>7 (6)</td>
<td>1 (1)</td>
<td>125 (9)</td>
<td>.005</td>
</tr>
<tr>
<td>Native American</td>
<td>7 (1)</td>
<td>1 (1)</td>
<td>0</td>
<td>16 (1)</td>
<td>.464</td>
</tr>
<tr>
<td>Other</td>
<td>50 (5)</td>
<td>10 (9)</td>
<td>8 (7)</td>
<td>67 (5)</td>
<td>.001</td>
</tr>
<tr>
<td><strong>Year of transplant</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1988-1995</td>
<td>137 (13)</td>
<td>18 (16)</td>
<td>18 (15)</td>
<td>213 (15)</td>
<td>.003</td>
</tr>
<tr>
<td>1996-2000</td>
<td>253 (24)</td>
<td>26 (23)</td>
<td>37 (31)</td>
<td>376 (27)</td>
<td>.722</td>
</tr>
<tr>
<td>2001-2005</td>
<td>356 (33)</td>
<td>44 (39)</td>
<td>39 (33)</td>
<td>506 (36)</td>
<td>.482</td>
</tr>
<tr>
<td>2006-2009</td>
<td>317 (30)</td>
<td>24 (21)</td>
<td>25 (21)</td>
<td>296 (21)</td>
<td>.328</td>
</tr>
<tr>
<td>Median follow-up of survivors, mo (range)</td>
<td>83 (3-244)</td>
<td>60 (19-205)</td>
<td>69 (12-157)</td>
<td>72 (3-229)</td>
<td>.465</td>
</tr>
</tbody>
</table>

NA, not available.
*Data has been modeled to adjust for oversampling of deceased patients due to a lack of consent for NMDP cases before 2003.
†Completeness index follows: Percent with 1-year follow-up: overall: 99%; percent with 3-year follow-up: overall: 95%; percent with 5-year follow-up: overall: 89%.
‡One or more locus is homozygous in the 8/8 matched category.
§This figure is the log-rank P value.

Results

A total of 2687 recipients of unrelated donor hematopoietic stem cell transplantation were included in the analysis. The 3 HLA mismatched comparison groups (N = 1624) included 112 (6.9%) transplant pairs designated as 7/8 HVG MM, 119 (7.3%) as 7/8 GVH MM, and 1393 (85.8%) as 7/8 bidirectional MM (Table 2). The outcome of these transplantations was compared with the 8/8 matched group (P < .0001) (Table 3). Pairwise comparisons between the 8/8 group and mismatched groups revealed differing effects similar to the analysis of overall survival. The 7/8 GVH MM and 7/8 bidirectional groups had significantly worse disease-free survival than the 8/8 match group. This difference did not reach statistical significance in the comparison between the 8/8 and 7/8 HVG MM groups (HR 1.38, 95% CI 1.07-1.78, P = .013). No significant difference was observed among the 3 7/8 mismatched groups (P = .60).

Transplant-related mortality

TRM was significantly associated with recipient CMV positivity (P = .008) and increasing donor age. After adjusting for significant covariates, significant differences were found between the 8/8 matched group and the mismatched groups (P < .0001) (Table 3). Pairwise comparisons between the 8/8 group and mismatched groups revealed differing effects similar to the analysis of overall survival. The 7/8 GVH MM and 7/8 bidirectional groups had significantly worse TRM compared with the 8/8 group. The 7/8 HVG group was not significantly different from the 8/8 group (HR 1.44, 95% CI 1.05-1.97, P = .025). No significant differences were observed among the 3 7/8 mismatched groups (P = .46).

Relapse

No significant associations were found with relapse, including the HLA match groups (P = .27).

Acute GVHD

Acute GVHD grades III-IV was significantly associated with intermediate or advanced disease (P = .002), peripheral blood stem cell grafts (P = .003), non-Caucasian recipients (P = .02), male recipients (P = .005), and transplantations before 2001 (P < .0001). After adjusting for significant covariates, significant differences were noted between the 8/8 matched group and the 7/8 GVH MM (P < .0001) and 7/8 bidirectional mismatched (P < .0001) groups (Table 3). Acute

Disease-free survival

Disease-free survival was significantly associated with recipient CMV positivity (P = .006) and increasing recipient age (P < .0001). After adjusting for significant covariates, significant differences were found between the 8/8 matched group and the mismatched groups (P < .0001) (Table 3). Pairwise comparisons between the 8/8 group and mismatched groups revealed differing effects similar to the analysis of overall survival. The 7/8 GVH MM and 7/8 bidirectional groups had significantly worse disease-free survival than the 8/8 match group. This difference did not reach statistical significance in the comparison between the 8/8 and 7/8 HVG MM groups (HR 1.38, 95% CI 1.07-1.78, P = .013). No significant difference was observed among the 3 7/8 mismatched groups (P = .60).
GVHD III-IV was not significantly different between the 8/8 and 7/8 HVG mismatched groups ($P = .39$). A comparison of the 7/8 mismatched groups found that both the 7/8 GVH MM and 7/8 bidirectional mismatched groups had significantly higher rates of acute GVHD than the 7/8 HVG mismatched group ($P = .003$) (Figure 1). There was no significant difference between the 7/8 GVH and the 7/8 bidirectional mismatched groups in acute GVHD ($P = .26$).

**Chronic GVHD**

Chronic GVHD was significantly associated with the use of in vivo T-cell depletion ($P < .0001$) and non-Caucasian recipients ($P = .04$). After adjusting for the significant covariates, no association was found with the HLA match group ($P = .71$).

**Neutrophil engraftment**

Neutrophil engraftment was significantly associated with the use of female donors into male recipients ($P < .0001$). After adjusting for the significant covariate, no association was found with the HLA match group ($P = .49$).

**Graft failure**

Graft failure was significantly associated with advanced disease ($P = .008$). After adjusting for the significant covariate, no significant difference was found between the 8/8 matched group and the mismatched groups for graft failure ($P = .06$). In addition, no significant differences were observed among the 3 7/8 mismatched groups ($P = .74$).

**Causes of death**

The primary causes of death, as reported by the centers in the various groups, were reviewed. The 7/8 bidirectional and GVH MM groups had slightly higher deaths attributed to GVHD, compared with the 8/8 and 7/8 HVG MM groups, 18.2% and 18.0% vs 14.9% and 14.3%, respectively. The 7/8 HVG MM group had more deaths attributed to graft rejection than the 8/8, 7/8 GVH MM, and 7/8 bidirectional groups, 9.5% vs 0.6%, 1.1%, and 1.6%, respectively. The 8/8 group had more deaths due to primary disease than the 7/8 groups, 32.2% vs 22.5% to 28.6%, respectively.

**Power limitations**

The 7/8 HVG and 7/8 GVH groups represented only 16% (8% per group) of all the 7/8 mismatches in the study population. To address concerns about power limitations in the data set, a power calculation based on the frequency of the 7/8 HVG MM, 7/8 GVH MM, and 7/8 bidirectional groups generated for the primary outcome of survival. The number of cases required to detect a difference between the 7/8 bidirectional group and 7/8 HVG or 7/8 GVH with 80% power is 19890 or 13833, respectively.
required sample sizes suggest that we need a much larger sample in order to detect the differences between bidirectional mismatches and GVH or HVG mismatch groups, and that any effects, if present, are not clinically significant.

Discussion

When no 8/8 matched donor exists for a patient, several options exist for a graft source including a 7/8 mismatched unrelated donor, umbilical cord blood, or a related haploidentical donor. While 7/8 mismatched unrelated donor transplantations have a 9% to 10% reduction in overall survival, this treatment may provide the best option for some patients. This study focused on developing guidelines for unrelated donor selection in the case where either the patient or a potential 7/8 matched donor is homozygous at the matched locus.

The major impact of homozygosity in the 7/8 mismatched groups is observed for acute GVHD. The 7/8 HVG MM group differs significantly from the 7/8 GVH MM and 7/8 bidirectional mismatch groups and is not significantly different from the 8/8 match group for acute GVHD. The associations of the histocompatibility groups with overall and disease-free survival are predominantly due to the impact of overall matching differences between 8/8 and 7/8, as previously observed in Lee et al. However, the decrease in the probability of acute GVHD in the 7/8 HVG MM group likely accounts for improved survival, as evidenced by the lack of a statistical difference from the 8/8 matched group for overall survival. The reduced acute GVHD observed in the 7/8 HVG MM grafts likely results from the absence of a mismatch from the perspective of the donor’s immune system, matching of the shared allele, and an apparent lack of a donor-derived immune response to its increased dose (ie, 2 allele copies in the homozygous recipient vs 1 in the donor).

It might be anticipated that a reduction in the incidence of GVHD in the 7/8 HVG MM grafts might result in an increased rate of relapse, but no significant association was observed. However, since overall and disease-free survival is not different for the 3 7/8 MM groups, a trend toward higher risk of relapse may be negating the positive impact of less GVHD for the HVG MM group.

The results of our study do not support previous observations. There was no impact on neutrophil engraftment or secondary graft failure observed with HLA homozygosity in a 7/8 unidirectional HVG MM, as previously noted by the Seattle group. The small sample size in the Seattle study, the difference in graft source (only bone marrow), the lower resolution of HLA typing used to define match categories, or differences in the immune competence of the recipients (CML only) may have given rise to these differences with our results. Our results regarding engraftment and graft failure are somewhat surprising in that one might expect that the 7/8 unidirectional mismatched grafts in which the recipient is homozygous and the donor heterozygous would result in immune recognition of the graft as foreign. The reported causes of death would appear to support the expected observation with the higher amount of death attributed to graft failure in the 7/8 HVG MM group (9.5% vs <2%). However, this did not come out in the statistical models of engraftment or graft failure as significant. Perhaps the disease status or conditioning of the recipient reduces the recipient’s ability to respond.

Other studies have also examined the role of HLA homozygosity in the selection of umbilical cord blood units, but with varying results. Because this stem cell source has a different cellular composition when compared with marrow or peripheral blood stem cell preparations, there may be differing effects of HLA matching on outcome than were observed in this study.

It is possible that engraftment failures observed in some homozygous recipients, as well as in bidirectional mismatched recipients, might be attributed primarily to the presence of preformed HLA-directed antibodies rather than de novo allorecognition of the graft. In fact, in solid organ transplantation, HLA homozygotes in general appear to be more sensitized to foreign HLA (Ilias Doxiadis, written communication). Evaluation of sensitization in the selection of a mismatched donor is used to reduce the likelihood of any potential immune response and should be considered, particularly for an HLA homozygous patient.

In summary, for unrelated donor selection, unidirectional mismatches in the GVH vector should be considered as the same level of risk as 7/8 bidirectional mismatches. For HLA homozygous recipients, the pool of potential donors can be expanded since there is no need to avoid a mismatch at the homozygous locus. In fact, HLA homozygous recipients receiving an HLA heterozygous graft will have a reduced risk of acute GVHD, and these 7/8 HVG MM donors might be preferred over a 7/8 mismatch at a heterozygous locus. These guidelines are summarized in Table 1.

Acknowledgments

This research was supported, in part, by funding from the Office of Naval Research (N00014-11-1-0590 and N00014-10-1-0199) (C.K.H.), and the National Cancer Institute (P30 CA51008) (L. Weiner). The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases; Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; contract HHSN234200637015C with the Health Resources and Services Administration (HRSA/DHHS); 2 grants (N00014-10-1-0204 and N00014-11-1-0339) from the Office of Naval Research; and grants from Allos, Inc, Amgen, Inc, Angioblast, Ariad, Be the Match Foundation, Blue Cross and Blue Shield Association, Buchanan Family Foundation, CaridianBCT, Celgene Corporation, CellGenix GmbH, Children’s Leukemia Research Association, Fresenius Biotech North America, Inc, Gamida Cell–Teva Joint Venture Ltd, Genentech, Inc, Genzyme Corporation, GlaxoSmithKline, Histogenetics, Inc, Kiadis Pharma, The Leukemia & Lymphoma Society, The Medical College of Wisconsin, Merck & Co, Inc, Millennium: The Takeda Oncology Co, Milliman USA, Inc, Miltenyi Biotec, Inc, National Marrow Donor Program, OptumHealth Care Solutions, Inc, Osiris Therapeutics, Inc, Otsuka America Pharmaceutical, Inc, RemedyMD, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals, Soligenix, Inc, StemCyte, A Global Cord Blood Therapeutics Co, Stemsoft Software, Inc, Swedish Orphan Biovitrum, Tarix Pharmaceuticals, Teva Neuroscience, Inc, Therakos, Inc, and Wellpoint, Inc, as well as an anonymous donation to the Medical College of Wisconsin. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government.

Authorship


Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Stephen Spellman, Center for International Blood and Marrow Transplant Research, 3001 Broadway St NE, Minneapolis, MN 55413; e-mail: spspellma@nmdp.org.

References


The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors